Roberto Contieri

Urologist @istitutotumori
via @HumanitasMilano @MDAndersonNews @NKI_nl
Member @EAU_YAUrotheli
Member @IBCG_BladderCA

[Roberto Contieri @RobertoContieri]

❓️Can we avoid ReTURBT in selected patients with T1 NMIBC? ✅️ According to our study YES!
👥️A response-based approach can spare up to 71% of ReTURBT reducing overtreatment

Full paper➡️https://t.co/dmugDLY4Wm

@EurUrolOncol @urotoday @Uroweb @oncodaily @IBCG_BladderCA

[UroToday.com @urotoday]

A multi-center study examines maintenance schedules for intermediate-risk #NMIBC. @RobertoContieri @IstTumori joins @UroDocAsh @UTMDAnderson to discuss the results which include two-year recurrence-free survival of 55% with no maintenance versus 78% with any maintenance. Classification and regression tree analysis identified optimal cutoff at more than six monthly instillations. #WatchNow on UroToday > https://t.co/G4Mw1OB0cA

[Max Kates @MaxKates]

1) Approval based on marginal improvements in efficacy (without improvement to CSS/OS)
2) Toxicity that isn't G5 (death) doesn't seem to impact approval. 10-15% serious autoimmune AEs in NMIBC is deemed ok
3) little weight given to efficacy vs toxicity balance of a drug

[Roberto Contieri @RobertoContieri]

Excellent lecture by @SScagliarini_ on the growing importance of patient-reported outcomes in oligometastatic RCC. A crucial reminder that beyond oncologic endpoints, understanding the patient perspective is essential to truly optimize treatment strategies.
@Synergy_Uro
@Uroweb

[Roberto Contieri @RobertoContieri]

Great pleasure having Prof. Axel Bex at @Synergy_Uro discussing the evolving landscape of locally advanced RCC. Excellent insights and stimulating discussion on current challenges and future directions in kidney cancer care. @eau_yuo
@EAUYAU_RenalCa
@UrowebESU
@EAU_Uroonco

[SYNERGY @Synergy_Uro]

The definitive #SYNERGY26 programme is out
📆 28–29 May | 📍 Naples

Locally-advanced & Oigometastatic GU cancers Edition.

Program: https://t.co/Gx1pBWHGEk

[Roberto Contieri @RobertoContieri]

As every year, a packed room for the AUA-IBCG Forum, taking place right now in Salon H.

Great discussions and energy around the future of bladder cancer care and research.

#AUA2026 #BladderCancer @IBCG_BladderCA @UroDocAsh

[OncoDaily @oncodaily]

Synergy 2026: A Global Exchange on Prostate, Kidney, and Bladder Cancer - Roberto Contieri (@RobertoContieri)

https://t.co/A7ZOyVYLPL

#OncoDaily #Oncology #Cancer #Health #Medicine #MedX

[SYNERGY @Synergy_Uro]

SYNERGY 2026
🗓️ 28-29 May 2026
📍 Naples, Italy

Preliminary Program: https://t.co/Gx1pBWHGEk

✉️ Information & participation: [email protected] - [email protected]

[Niyati Lobo @niyatilobo]

To escalate or de-escalate treatment in BCG-naive HR NMIBC?

Our thoughts on the recent JCOG1019 trial by Kitamura et al @EUplatinum

Free access to full text 👇🏽

https://t.co/xH5ios6rmT

@RobertoContieri @LAUrology_NL @UroDocAsh

[UroToday.com @urotoday]

A multi-center study examines maintenance schedules for intermediate-risk #NMIBC. @RobertoContieri @IstTumori joins @UroDocAsh @UTMDAnderson to discuss the results which include two-year recurrence-free survival of 55% with no maintenance versus 78% with any maintenance. Classification and regression tree analysis identified optimal cutoff at more than six monthly instillations. #WatchNow on UroToday > https://t.co/G4Mw1OB0cA

[European Urology Oncology @EurUrolOncol]

Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial by Roberto Contieri et al

Read the full article: https://t.co/6UJQAYDEE3

We thank the authors for trusting EUO to publish your work

@robertocontieri

@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@UroDocAsh
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect

[IBCG @IBCG_BladderCA]

The International Bladder Cancer Group Travel Award to support outstanding fellows and early-career academic faculty committed to advancing the field of bladder cancer is now offered annually to provide emerging leaders the opportunity to participate in the IBCG Annual Retreat.

Details at link: https://t.co/y8zbYkeLac
#BladderCancer #IBCG26

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Pleased to share that the 2026 @NCCN Bladder Cancer Guidelines now incorporate the @IBCG_BladderCa risk stratification framework for intermediate-risk NMIBC.

A milestone reflecting more than a decade of collaborative work by colleagues worldwide

https://t.co/VWFvAqRq4y

@UrogerliMD @drtanws @shilpaonc @pjhensley11 @mouwlab @AndreaNecchi @LAUrology_NL @AmirHorowitz @karima_oualla @PGrivasMDPhD @paolo_gontero @pcvblack @MaxKates @SpiessPhilippe @RobertoContieri @KKBree @LauraBukavinaMD @MRoupret @joanfundi @UroToday @BladderCancerUS @WorldBladderCan

[Aleksander Ślusarczyk @slusarczyk_alek]

We validated BCG failure classifications
~5-year progression ≈30% in both BCG-exposed and BCG-unresponsive groups—but salvage RC is used more often in BCG-unresponsive pts
https://t.co/ee1fJpr9Gq @Pietro9609 @UroMoschini @BenjaminPradere @RobertoContieri @SBoorjian @BJUIjournal

[OncoDaily @oncodaily]

Roberto Contieri Shares Key Insights on Bladder Cancer Care at EAU 2026

@RobertoContieri

https://t.co/RRPi1vvCih

#OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

[Sia Daneshmand, M.D. @siadaneshmand]

@tonivilaseca presenting promising early data for intravesical erdafitinib (Erda-iDRS) “TAR 210” in NMIBC presented at #EAU26
➡️ 83% 12-mo RFS as adjuvant therapy in HR NMIBC (n=26)
➡️ 89% CR at 6 months in IR NMIBC ablative cohort
Targeted #FGFR therapy moving earlier into NMIBC disease states. @JoshMeeks @DrFelixGuerrero @IBCG_BladderCA @BladderCancerUS

[VJ Oncology @VJOncology]

Which #NMIBC patients may safely receive de-intensified treatment?

At #EAU26 @RobertoContieri (@istitutotumori) discusses risk stratification for de-escalation, findings from the ROBUUST database on histological subtypes, and optimizing mitomycin C maintenance in intermediate-risk Ta disease

@Uroweb #GUsm #BladderCancer

[UroToday.com @urotoday]

State-of-the-art lecture treatment de-intensification in #NMIBC. Presentation by @RobertoContieri @IstTumori. #EAU26 written coverage by @chavarriagaj @PSH_Urology > https://t.co/1DViX1tSjm @Uroweb

[Julian Chavarriaga @chavarriagaj]

#EAU26 @RobertoContieri “Less is more” in select NMIBC
🔹 Office-based fulguration
🔹 Active surveillance
🔹 Chemoablation
🎯 The key is patient selection.
@uroweb @UroToday

[Niyati Lobo @niyatilobo]

Excellent case for de-escalating management of LGTa #bladdercancer by @RobertoContieri

LG Ta has low progression risk & negligible CSM yet…

We overtreat LGTa
We oversurveil LGTa

Active surveillance in well selected pts is safe, cost-effective & maintains excellent QoL #EAU26